Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Short term Debt (2016 - 2022)

Acro Biomedical (ACBM) has 7 years of Short term Debt data on record, last reported at $78826.0 in Q4 2022.

  • For Q4 2022, Short term Debt rose 280.05% year-over-year to $78826.0; the TTM value through Dec 2022 reached $78826.0, up 280.05%, while the annual FY2022 figure was $78826.0, 280.05% up from the prior year.
  • Short term Debt reached $78826.0 in Q4 2022 per ACBM's latest filing, roughly flat from $78594.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $257567.0 in Q1 2021 and bottomed at $3266.0 in Q4 2018.
  • Average Short term Debt over 5 years is $86005.2, with a median of $70306.0 recorded in 2020.
  • The widest YoY moves for Short term Debt: up 994.08% in 2018, down 92.11% in 2018.
  • A 5-year view of Short term Debt shows it stood at $3266.0 in 2018, then surged by 704.62% to $26279.0 in 2019, then soared by 824.51% to $242951.0 in 2020, then tumbled by 91.46% to $20741.0 in 2021, then surged by 280.05% to $78826.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $78826.0 in Q4 2022, $78594.0 in Q3 2022, and $21245.0 in Q2 2022.